837 related articles for article (PubMed ID: 25070581)
1. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
2. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
4. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
5. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Zhang PF; Li KS; Shen YH; Gao PT; Dong ZR; Cai JB; Zhang C; Huang XY; Tian MX; Hu ZQ; Gao DM; Fan J; Ke AW; Shi GM
Cell Death Dis; 2016 Apr; 7(4):e2201. PubMed ID: 27100895
[TBL] [Abstract][Full Text] [Related]
6. BDE-99 (2,2',4,4',5-pentabromodiphenyl ether) triggers epithelial-mesenchymal transition in colorectal cancer cells via PI3K/Akt/Snail signaling pathway.
Wang F; Ruan XJ; Zhang HY
Tumori; 2015; 101(2):238-45. PubMed ID: 25908029
[TBL] [Abstract][Full Text] [Related]
7. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
[TBL] [Abstract][Full Text] [Related]
8. Involvement of PI3K/Akt pathway in the inhibition of hepatocarcinoma cell invasion and metastasis induced by SASH1 through downregulating Shh-Gli1 signaling.
Sun C; Zhang Z; He P; Zhou Y; Xie X
Int J Biochem Cell Biol; 2017 Aug; 89():95-100. PubMed ID: 28600143
[TBL] [Abstract][Full Text] [Related]
9. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling.
Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J
Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
Du R; Wu S; Lv X; Fang H; Wu S; Kang J
J Exp Clin Cancer Res; 2014 Dec; 33(1):105. PubMed ID: 25499255
[TBL] [Abstract][Full Text] [Related]
11. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
12. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
15. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
17. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
[TBL] [Abstract][Full Text] [Related]
18. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.
Ogunwobi OO; Liu C
Clin Exp Metastasis; 2011 Dec; 28(8):721-31. PubMed ID: 21744257
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
